Community
Sobi Italia emphasizes the importance of patient advocacy in driving the pharmaceutical industry forward, highlighting their commitment to patient-centred care and collaboration with patient organizations. Carla Rapaccioli, Head of Community Engagement, states that advocacy is integral to their business strategy, ensuring that the voices of rare disease patients and their caregivers are prioritized.
The highest scores were achieved ... with patient organisations and services ‘beyond medication’. ... “This is not just a ranking, but confirmation that our commitment is recognised by those who, every day, represent and support people living with a rare disease,” explains Carla Rapaccioli, Head of Community Engagement & Communication at Sobi Italia. For the company, advocacy is not a separate ... The highest scores were achieved in the areas of patient-centred care, relationships with patient organisations and services ‘beyond medication’. ... “This is not just a ranking, but confirmation that our commitment is recognised by those who, every day, represent and support people living with a rare disease,” explains Carla Rapaccioli, Head of Community Engagement & Communication at Sobi Italia. For the company, advocacy is not a separate activity from the rest of the business: “It means working to ensure that the voices of people with rare diseases and their carers are heard and valued,” says Rapaccioli, “and it is an integral part of our sustainability strategy: creating value means generating a tangible and lasting impact for the communities we serve.” In the PatientView 2025/2026 ranking, based on the opinions of 502 organisations in 63 countries, Sobi has retained its top spot for the second year running Looking ahead, Rapaccioli is banking on a model of advocacy that is less top-down and more collaborative amongst the various stakeholders in the system: ‘Advocacy in the future will increasingly be the result of a collective effort, in which institutions, the scientific community, patient organisations and industry each play their part in identifying practical solutions to improve diagnosis, care management, access to innovation and equity of care’. The recognition of PatientView, he concludes, “reminds us that genuine relationships and collaboration with the rare diseases community are the starting point for building them”. The operational framework is the global “Unite4Rare” initiative, through which the company says it translates feedback from communities into concrete initiatives: in Italia, over the last 12–18 months, this has included campaigns such as Cl3Ar on kidney health, projects to actively engage people with immune thrombocytopenia (ITP), programmes developed with FedEmo on haemophilia, and the ‘Rare Means Care’ initiative for Rare Disease Day. However, it is in the area of access, rather than that of recognition, that Rapaccioli identifies the outstanding issues for the Italian system. ‘One of the most significant issues remains early diagnosis: for many rare conditions, the diagnostic process can still be long and complex, with a significant impact on patients and carers,’ he observes.
Original title: “Rare diseases: when patients drive the pharmaceutical industry forward - Il Sole 24 ORE”